N.M. Code R. § 16.19.26.10

Current through Register Vol. 35, No. 11, June 11, 2024

Section 16.19.26.10 - TOBACCO CESSATION DRUG THERAPY

A.Protocol:

(1) Prescriptive authority for tobacco cessation drug therapy shall be exercised solely in accordance with the written protocol for tobacco cessation drug therapy approved by the board.

(2) Any pharmacist exercising prescriptive authority for tobacco cessation drug therapy must maintain a current copy of the written protocol for tobacco cessation drug therapy approved by the board.

B.Education and training:

(1) The pharmacist must successfully complete a course of training, accredited by the accreditation council for pharmacy education (ACPE), in the subject area of tobacco cessation drug therapy provided by:

(a) the department of health;

(b) health and human services; or

(c) a similar health authority or professional body approved by the board.

(2) Training must include study materials and instruction in the following content areas:

(a) mechanisms of action for contraindications, drug interactions, and monitoring cessation;

(b) current standards for prescribing tobacco cessation drug therapy;

(c) identifying indications for the use of tobacco cessation drug therapy;

(d) interviewing patient to establish need for tobacco cessation drug therapy;

(e) counseling patient regarding the safety, efficacy and potential adverse effects of drug products for tobacco cessation;

(f) evaluating patient's medical profile for drug interaction;

(g) referring patient follow-up care with primary healthcare provider;

(h) informed consent;

(i) record management;

(j) management of adverse events, including identification, appropriate response, documentation and reporting;

(k) reimbursement procedures and tobacco cessation drug therapy and education coverage by federal, state and local entities.

(3) Continuing education: Any pharmacist exercising prescriptive authority for tobacco cessation drug therapy shall complete a minimum of 0.2 CEU of ACPE approved tobacco cessation drug therapy related continuing education every two years. Such continuing education shall be in addition to requirements in 16.19.4.10 NMAC.

C.Authorized drugs:

(1) Prescriptive authority shall be limited to tobacco cessation drug therapy including prescription and non-prescription therapies.

(2) Prescriptive authority for tobacco cessation drug therapy shall be limited to those drugs delineated in the written protocol approved by the board.

D.Records:

(1) The prescribing pharmacist must generate a written or electronic prescription for any dangerous drug authorized.

(2) Informed consent must be documented in accordance with the approved protocol for tobacco cessation drug therapy and a record of such consent maintained in the pharmacy for a period of at least three years.

E.Notification: Upon signed consent of the patient, the pharmacist shall notify the patient's designated physician or primary care provider of tobacco cessation drug therapy prescribed.

N.M. Code R. § 16.19.26.10

16.19.26.10 NMAC - N, 12-15-02; 16.19.26.10 NMAC - Rn, 16.19.26.9 NMAC & A, 07-15-04; Amended by New Mexico Register, Volume XXVI, Issue 16, August 28, 2015, eff. 9/6/2015, Amended and Renumbered from 16.19.26.11 by New Mexico Register, Volume XXXII, Issue 10, May 25, 2021, eff. 5/31/2021